Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Spatial Analysis Reveals Gene Expression and Microenvironmental Changes in the Transition of Nevus to Melanoma.

Cancer research·2026
Same author

Utility of combined CD39/CD73/CD38 expression for the detection of malignant T cells in Sézary syndrome.

British journal of haematology·2026
Same author

Social status impacts T-cell responses through synapse strength in the prefrontal cortex.

Cell research·2026
Same author

Temporal and spatial composition of the tumor microenvironment predicts response to immune checkpoint inhibition in metastatic TNBC.

Nature cancer·2026
Same author

Guidelines for T cell nomenclature.

Nature reviews. Immunology·2025
Same author

Pyroglutamation of cell surface proteins CD47 and TRP1 by glutaminyl cyclase modulates therapeutic antibody binding.

Communications biology·2025

Related Experiment Video

Updated: Dec 21, 2025

Mitigation of Blood Borne Cell Attachment to Metal Implants through CD47-Derived Peptide Immobilization
08:13

Mitigation of Blood Borne Cell Attachment to Metal Implants through CD47-Derived Peptide Immobilization

Published on: December 3, 2020

4.9K

The CD47-SIRPα Immune Checkpoint.

Meike E W Logtenberg1, Ferenc A Scheeren2, Ton N Schumacher3

  • 1Division of Molecular Oncology and Immunology, Oncode Institute, the Netherlands Cancer Institute, Amsterdam, the Netherlands.

Immunity
|May 21, 2020
PubMed
Summary

The CD47-SIRPα axis, a key myeloid cell regulator, is crucial for tissue balance and a potential therapeutic target. Understanding this "don't eat me signal" pathway offers new treatment avenues for diseases like cancer and fibrosis.

More Related Videos

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

53.9K
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

950

Related Experiment Videos

Last Updated: Dec 21, 2025

Mitigation of Blood Borne Cell Attachment to Metal Implants through CD47-Derived Peptide Immobilization
08:13

Mitigation of Blood Borne Cell Attachment to Metal Implants through CD47-Derived Peptide Immobilization

Published on: December 3, 2020

4.9K
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

53.9K
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

950

Area of Science:

  • Immunology
  • Cell Biology
  • Therapeutics

Background:

  • Myeloid cell cytotoxic activity relies on signals from activating and inhibitory receptors.
  • Cluster of Differentiation 47 (CD47) on healthy and cancer cells signals myeloid cells via Signal-regulatory protein alpha (SIRPα) to prevent phagocytosis.
  • This CD47-SIRPα interaction is vital for maintaining physiological tissue homeostasis.

Purpose of the Study:

  • To review the current understanding of the CD47-SIRPα axis in tissue homeostasis.
  • To explore the CD47-SIRPα axis as a therapeutic target in oncology, fibrotic diseases, atherosclerosis, and stem cell therapies.
  • To identify knowledge gaps and areas for future research in exploiting this pathway.

Main Methods:

  • Literature review of existing research on the CD47-SIRPα pathway.
  • Analysis of the role of CD47-SIRPα in physiological processes.
  • Evaluation of therapeutic potential and challenges.

Main Results:

  • The CD47-SIRPα axis is a critical regulator of myeloid cell function.
  • Dysregulation of CD47-SIRPα contributes to various pathologies, including cancer and fibrotic diseases.
  • Targeting CD47-SIRPα shows promise in preclinical models for multiple therapeutic applications.

Conclusions:

  • The CD47-SIRPα axis is a significant target for modulating immune responses and treating diseases.
  • Further research is needed to optimize therapeutic strategies and overcome potential resistance mechanisms.
  • Understanding this myeloid checkpoint is essential for advancing treatments in oncology and beyond.